OROBOROS
Dead / Abandoned — Abandoned — no statement of use filed (as of 04 Jul 2022)
What this means for you
This application is over — abandoned 04 Jul 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88723015
- Mark type
- Stylized text
- Filed
- 11 Dec 2019
- Published for opposition
- 07 Apr 2020
- Abandoned
- 04 Jul 2022
- Attorney of record
- Gwenn Roos
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for the treatment of cancer, autoimmune, immune mediated, and inflammatory diseases and disorders, a full line of nucleic acid pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics
- Class 042 — Scientific and technological services: Scientific research in the fields of nucleic acid pharmaceuticals, medicine, biologics, biotherapeutics, biosimilars and therapeutics
Owner
- ORNA THERAPEUTICS, INC., Cambridge, MA, US
- Oroboros, Inc., Cambridge, MA, US
- Oroboros, Inc., Cambridge, MA, US
Prosecution history
- 05 Jul 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 04 Jul 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 10 Feb 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Feb 2022 — SOU EXTENSION 3 GRANTED
- 02 Dec 2021 — SOU EXTENSION 3 FILED
- 07 Feb 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 04 Jan 2022 — NOTICE OF REVIVAL - E-MAILED
- 03 Jan 2022 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 03 Jan 2022 — PETITION TO REVIVE-GRANTED
- 03 Jan 2022 — TEAS PETITION TO REVIVE RECEIVED
- 03 Jan 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 03 Jan 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 28 May 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 May 2021 — SOU EXTENSION 2 GRANTED
- 26 May 2021 — SOU EXTENSION 2 FILED